Is Aging a Disease? The Scientific Debate

A Question With Billion-Dollar Consequences

At first glance, the question of whether aging is a disease might seem purely academic — a philosophical debate with little practical significance. In reality, how we classify aging has profound consequences for research funding, drug development, medical practice, and the lives of billions of people. The answer determines whether the pharmaceutical industry can develop and market drugs to treat aging, whether health insurance covers anti-aging interventions, and whether the scientific community prioritizes understanding aging itself or continues to fight its consequences one disease at a time.

The debate has intensified in recent years as the science of aging has advanced to the point where actual interventions appear feasible. For the first time in history, we are not asking whether aging can be treated but whether we should try.

The Case for Aging as a Disease

Biological Arguments

Proponents of classifying aging as a disease point to several biological realities:

Aging has identifiable hallmarks: The twelve hallmarks of aging (genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, disabled macroautophagy, chronic inflammation, and dysbiosis) describe specific, measurable molecular and cellular changes. These hallmarks meet the biological criteria for a pathological process.

Aging is the primary risk factor for disease: Age is the single greatest risk factor for cancer, cardiovascular disease, neurodegeneration, diabetes, and most other leading causes of death. Treating aging itself would address the root cause of these diseases rather than treating each individually.

Aging is modifiable: Research has demonstrated that the rate of aging can be altered in animal models through genetic, pharmacological, and lifestyle interventions. If aging were truly a fixed, immutable process, it could not be accelerated or decelerated. The fact that it can be modified suggests it behaves more like a disease process than an inevitable natural phenomenon.

Not all species age equally: Some organisms, including certain species of tortoises, rockfish, and naked mole-rats, show negligible senescence — they do not display the functional declines that characterize aging in most mammals. This suggests that aging is not a universal requirement of life but rather a specific biological program or failure mode.

Practical Arguments

Research funding: Classifying aging as a disease would enable pharmaceutical companies to pursue FDA-approved anti-aging drugs. Currently, the FDA does not recognize aging as an indication, meaning that even if a drug demonstrably slowed aging, it could not be approved and marketed for that purpose. This creates a massive barrier to investment in aging research.

The TAME precedent: The Targeting Aging with Metformin trial is specifically designed to establish aging as a treatable condition within the FDA framework. Its composite endpoint (time to first major age-related disease or death) frames aging as a unified process rather than a collection of individual diseases.

Healthcare efficiency: Treating aging itself could be far more cost-effective than treating its individual manifestations. An intervention that delays all age-related diseases by even a few years would save healthcare systems trillions of dollars while improving quality of life for millions.

The geroscience hypothesis: The central insight of geroscience is that the biological mechanisms of aging are the primary drivers of age-related disease. Targeting these mechanisms should delay or prevent multiple diseases simultaneously — a far more efficient approach than the current disease-by-disease model.

Historical Precedent

Other conditions once considered natural or inevitable have been reclassified as treatable diseases:

• Menopause: Once considered a natural phase of life, hormonal symptoms are now medically treatable
• Osteoporosis: Bone loss was once considered normal aging; it is now a diagnosable and treatable condition
• Erectile dysfunction: Once dismissed as normal aging, now recognized as a treatable condition
• Obesity: Increasingly recognized as a chronic disease rather than a lifestyle choice, opening new treatment paradigms

The Case Against Disease Classification

Philosophical Arguments

Universality: Aging affects every human being without exception. Diseases, by definition, are abnormal states. Calling a universal biological process a disease seems to conflate the normal with the pathological.

Medicalization of life: Critics argue that labeling aging as a disease medicalizes a natural part of the human experience, potentially creating anxiety, stigma, and unrealistic expectations. It could imply that growing old is inherently defective or broken, devaluing the experience of older adults.

Where does health end and disease begin?: If aging is a disease, when does it start? At birth? At 30? At the first detectable hallmark? The lack of a clear onset makes disease classification problematic.

Practical Concerns

Age discrimination: If aging is a disease, it could reinforce ageist attitudes by framing older people as inherently sick or defective. This could have implications for employment, insurance, and social treatment of elderly populations.

Resource diversion: Some argue that research funding spent on slowing aging might be better directed toward treating specific diseases that cause the most suffering, particularly in low-resource settings where infectious diseases and malnutrition remain more pressing concerns.

Unrealistic expectations: Classifying aging as a disease might create expectations that aging can be “cured,” leading to disappointment, exploitation by unscrupulous marketers, and erosion of trust in medical science.

Pharmaceutical profit motive: Critics worry that disease classification could lead to excessive medicalization of normal aging for pharmaceutical profit, with healthy older adults pressured to take expensive drugs of marginal benefit.

Scientific Caution

Incomplete understanding: While the hallmarks of aging are well-described, we do not yet fully understand the causal relationships between them or whether aging has a single unifying mechanism that could be targeted therapeutically. Classifying aging as a disease may oversimplify a complex, multi-factorial process.

Evolutionary perspective: From an evolutionary standpoint, aging may result from the decline of natural selection’s power after the reproductive period rather than from any specific pathological program. If aging is an evolutionary byproduct rather than a disease process, the disease metaphor may be misleading.

The WHO’s Compromise

ICD-11 and Code XT9T

In 2018, the World Health Organization released the 11th revision of the International Classification of Diseases (ICD-11), which included a new extension code, XT9T, for “ageing-related.” This code can be used alongside other diagnostic codes to indicate that a condition is associated with the aging process.

While XT9T falls short of classifying aging itself as a disease, it represents a significant step:

• It formally acknowledges that aging-related processes are medically relevant
• It provides a coding framework that could facilitate research on aging as a unified process
• It opens the door for health systems to track and potentially treat aging-related conditions more systematically

The Middle Ground

Many researchers have adopted a nuanced position: aging is not a disease in the traditional sense, but it is a pathological process that should be medically addressable. This view regards aging as a “condition” or “process” rather than a disease per se, while still advocating for its inclusion in medical frameworks.

Nir Barzilai, who leads the TAME trial, has proposed the term “indication” — aging should be recognized as an indication for pharmaceutical intervention, even if it is not formally called a disease. This would allow drug development targeting aging without requiring full disease classification.

What the Debate Means for You

The Current Landscape

Regardless of how aging is officially classified, the practical reality is evolving rapidly:

• Research funding: Government agencies including the NIA (National Institute on Aging) increasingly fund geroscience research targeting aging mechanisms
• Clinical trials: Multiple trials are testing interventions that target aging itself (TAME, senolytic trials, NAD+ trials)
• Longevity medicine: A growing number of physicians specialize in longevity medicine, incorporating biological age assessment and evidence-based interventions
• Supplement industry: Consumer interest in anti-aging compounds has created a massive market, though quality and evidence vary widely

What You Can Do Now

While the disease classification debate continues, the actions you can take are clear:

1. Address the modifiable factors: Exercise, nutrition, sleep, and stress management meaningfully influence the rate of biological aging regardless of how it is classified
2. Monitor biological age: Epigenetic clocks and other biomarkers provide feedback on your aging trajectory
3. Stay informed: The field is advancing rapidly; evidence-based interventions are likely to expand in coming years
4. Be appropriately skeptical: Not every product marketed as anti-aging has evidence behind it; the disease classification debate does not validate all anti-aging claims

The Bottom Line

The question of whether aging is a disease is ultimately less important than the recognition that aging is the primary driver of human suffering and death, and that it is, to a meaningful extent, modifiable. Whether we call it a disease, a condition, a process, or a treatable indication, the scientific community is increasingly aligned on the need to understand and intervene in aging itself rather than solely treating its downstream consequences. The classification debate may seem semantic, but its resolution will shape the trajectory of medical research, pharmaceutical development, and healthcare policy for decades to come.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional for personalized health guidance.